Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a development stage biotechnology company. The Company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), an alpha-synucleinopathy. Its proprietary target discovery engine... see more

Bullboard (NDAQ:PMN)

View:
Comment by M101on May 18, 2024 12:27pm

RE:RE:Performance Based

I agree with Farmer here because the MO seems logical, the company has stopped just short of doing anything which would generate big pharma interest, but 1b will cross that line so Boston Group ...more  
Comment by farmerlucyon May 17, 2024 10:31pm

RE:Performance Based

Promis is not in the hand s of a BOD's, it's the Boston Group. This has been the case ever since Promis got involved with them. Now just a matter ot seeing what they do with it. They  ...more  
Post by goldtechon May 17, 2024 1:05pm

Performance Based

So this Board wants more option shares as the price goes lower!!!!!! This passive rubber stamp Board does nothing in the way of creating any value for the company whatsoever and only think of ...more  
Post by Jonathon Brownon May 16, 2024 10:33am

Buzz on the Bullboards: Major developments amidst market dynamics

Post by Alex1726on May 16, 2024 7:26am

mab is not a convenient solution.

https://www.insiderfinancial.com/post/anavex-life-sciences-nasdaq-avxl-alzheimers-missing-link-next-target-of-meme-stock-mania
Comment by Alex1726on May 15, 2024 6:20pm

RE:RE:RE:RE:New Press Release - ProMIS Neurosciences Announces First Quarter 2024 Financial Results and Recent Highlights

What an idi ....ot after all thoses years still trying to figure what is going on when it is obvious that nothing is going on and DURING THIS TIME REAL COMPANIES MAKING REAL PROGRESS AND IN A NOT TOO ...more  
Post by Alex1726on May 15, 2024 6:16pm

Anavex is also working on it

Anavex Life Sciences Initiates Placebo-Controlled U.S. Phase 2 Clinical Trial of ANAVEX®3-71 in Schizophrenia Bristol Myers to acquire brain drug developer Karuna for $14B The deal would hand ...more  
Comment by M101on May 15, 2024 6:07pm

RE:RE:RE:New Press Release - ProMIS Neurosciences Announces First Quarter 2024 Financial Results and Recent Highlights

I imagine the Boston Group has left it up to the board to get some pharma deal done or come back to them at $2, but they're not budging. If so then a slight delay might be seen as a positive, but ...more  
Comment by Alex1726on May 15, 2024 5:19pm

RE:RE:RE:RE:RE:Still a scrap.

They're on the way for approval in Europe they say they will submit for approval this year. https://ca.finance.yahoo.com/news/anavex-received-agreement-committee-medicinal-123000450.html
Comment by Alex1726on May 15, 2024 5:12pm

RE:RE:RE:RE:RE:Still a scrap.

That was more than 2 days ago https://ca.finance.yahoo.com/news/anavex-life-sciences-corp-nasdaq-151830892.html Take a look at the last conference call with analysts . No one talked about that ...more  
Comment by Speyeder999on May 15, 2024 5:07pm

RE:RE:RE:RE:Still a scrap.

Thanks for the plug......and you're saying people should ignore the Class Action Lawsuit fiiled by investors 2 days ago, right?
Comment by Alex1726on May 15, 2024 5:00pm

RE:RE:RE:Still a scrap.

https://www.defenseworld.net/2024/05/12/anavex-life-sciences-nasdaqavxl-receives-buy-rating-from-hc-wainwright.html Anavex Life Sciences (NASDAQ:AVXL – Get Free Report)‘s stock had its “buy” rating ...more  
Comment by Alex1726on May 15, 2024 4:31pm

RE:RE:Still a scrap.

Don't waste your time with that lazy guys , what do you THINK Gene Williams will do during summer time : Working hard for shareholders? NO WAY. Oh by the way blarcamesine is a one daily pill.
Comment by Alex1726on May 15, 2024 4:24pm

RE:Still a scrap.

The study's outcome represents a noteworthy milestone, with blarcamesine being among the first drugs to exhibit efficacy on biomarkers of neurodegeneration. Moreover, blarcamesine demonstrated a ...more  
Post by Alex1726on May 15, 2024 4:07pm

Still a scrap.

Even the ones that failes(Annovis) has a greater market value. They just don't want to conduct real clinical trials.  Sell that scrap and buy anavex if you want to make money in AD. TAKE A ...more  
Comment by Speyeder999on May 15, 2024 3:18pm

RE:RE:New Press Release - ProMIS Neurosciences Announces First Quarter 2024 Financial Results and Recent Highlights

I'm going with sooner than later. With the company's current burn rate and 2,5M in cash and equivalents as of March 31, they'll run out of funds anytime now, if it hasn't happened ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities